InsiderTrades.com logo
Mardi Dier net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Mardi Dier Biography and Net Worth

Executive Vice President, Chief Financial Officer of Madrigal Pharmaceuticals

Ms. Dier has spent more than 20 years in executive financial leadership roles in the biopharmaceutical industry, with deep experience in operational and strategic decision making, capital raising, financial planning and accounting (FP&A), global supply chain management, investor relations and business development. She has held Chief Financial Officer positions at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc. Ms. Dier serves on multiple boards and is a member of the Board of Advisors for the Anderson School of Management at the University of California, Los Angeles (UCLA).

What is Mardi Dier's net worth?

The estimated net worth of Mardi Dier is at least $6.64 million as of March 6th, 2026. Ms. Dier owns 12,490 shares of Madrigal Pharmaceuticals stock worth more than $6,644,930 as of April 19th. This net worth evaluation does not reflect any other investments that Ms. Dier may own. Learn More about Mardi Dier's net worth.

How do I contact Mardi Dier?

The corporate mailing address for Ms. Dier and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on Mardi Dier's contact information.

Has Mardi Dier been buying or selling shares of Madrigal Pharmaceuticals?

Mardi Dier has not been actively trading shares of Madrigal Pharmaceuticals over the course of the past ninety days. Most recently, Mardi Dier sold 1,982 shares of the business's stock in a transaction on Friday, March 6th. The shares were sold at an average price of $430.87, for a transaction totalling $853,984.34. Following the completion of the sale, the chief financial officer now directly owns 12,490 shares of the company's stock, valued at $5,381,566.30. Learn More on Mardi Dier's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Kenneth Bate (Director), Fred Craves (Director), James Daly (Director), Mardi Dier (Executive Vice President, Chief Financial Officer), Paul Friedman (Director), Carole Huntsman (Chief Commercial Officer), Shannon Kelley (General Counsel), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 3 times. They purchased a total of 165,683 shares worth more than $61,921,142.32. During the last twelve months, insiders at the biopharmaceutical company sold shares 37 times. They sold a total of 441,687 shares worth more than $182,355,449.07. The most recent insider tranaction occured on March, 6th when CFO Mardi Dier sold 1,982 shares worth more than $853,984.34. Insiders at Madrigal Pharmaceuticals own 21.5% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 3/6/2026.

Mardi Dier Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2026Sell1,982$430.87$853,984.3412,490View SEC Filing Icon  
3/2/2026Sell1,183$427.21$505,389.439,257View SEC Filing Icon  
12/2/2025Sell4,173$578.34$2,413,412.8210,440View SEC Filing Icon  
See Full Table

Mardi Dier Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Mardi Dier's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $532.02
Low: $522.81
High: $536.86

50 Day Range

MA: $474.71
Low: $425.85
High: $546.89

2 Week Range

Now: $532.02
Low: $265.00
High: $615.00

Volume

345,678 shs

Average Volume

374,211 shs

Market Capitalization

$12.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A